Candel Therapeutics, Inc.

CADL

Candel Therapeutics, Inc.

CADL

Insider Sentiment (TTM):

Last Purchase:2026-02-23Last Sale:2025-07-28Shares Purchased (TTM):550,458Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:43,310,452Shares Outstanding:62,361,897Institutional Ownership Pct.:69.45%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	202	195	120	87	101	92	103	17	21	26	35	43
Prepaid Expense And Other Assets Current	3	3	2	3	3	1	1	2	1	1	1	2
Assets Current	204	198	121	90	104	93	104	18	23	27	37	45
Property Plant And Equipment Net	2	2	2	1	2	2	2	2	3	3	3	4
Operating Lease Right Of Use Asset	1	2	2	2	0	0	1	1	1	1	1	1
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	0	0	0	0	0	0	0	0	0
Assets	208	202	125	94	106	96	107	22	26	31	41	50
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	3	1	1	2	1	0	0	0	0	0	0
Accrued Liabilities Current	7	3	7	5	4	3	5	5	3	3	4	3
Long Term Debt Current	-	-	0	4	7	9	10	10	10	10	9	6
Operating Lease Liability Current	0	0	0	0	1	1	1	1	1	1	1	1
Other Liabilities Current	0	0	0	-	-	-	0	-	-	-	-	0
Liabilities Current	13	7	9	11	15	20	38	15	14	14	14	10
Deferred Revenue Noncurrent	0	0	0	-	-	-	0	-	-	-	-	0
Long Term Loans From Bank	47	46	46	0	0	0	2	4	7	9	12	14
Other Long Term Debt Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Liability Noncurrent	1	1	1	2	0	0	0	1	1	1	1	1
Liabilities	82	64	73	13	16	21	41	37	36	25	28	27
Stockholders Equity
Common Stock Value	1	1	1	1	1	0	0	0	0	0	0	0
Treasury Stock Value	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Additional Paid In Capital Common Stock	404	377	282	281	280	259	259	163	158	151	150	149
Retained Earnings Accumulated Deficit	-278	-239	-230	-201	-190	-185	-192	-178	-167	-145	-137	-126
Stockholders Equity	126	138	52	80	90	75	66	-15	-10	6	13	23
Liabilities And Stockholders Equity	208	202	125	94	106	96	107	22	26	31	41	50
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	-	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	76	73	55	55	55	49	47	32	31	29	29	29
Shares Outstanding	76	73	55	55	55	49	47	32	31	29	29	29

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.49%	10.33%	10.77%	-	-	-	-	-	-	-	-	-
2025	11.96%	-5.47%	16.59%	-17.22%	-7.95%	-10.93%	15.62%	18.00%	26.68%	0.40%	29.92%	66.67%
2024	-33.18%	-45.61%	-49.44%	5.14%	13.87%	-9.59%	19.53%	114.42%	64.42%	-39.29%	-33.50%	-31.36%
2023	-	-	-	-	-	-	3.45%	68.97%	38.51%	227.22%	627.85%	361.39%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	16.09	28.05	13.49	8.25	7.04	4.64	2.77	1.18	1.62	2.00	2.59	4.37
Quick Ratio	15.89	27.63	13.31	7.96	6.84	4.59	2.74	1.08	1.53	1.90	2.50	4.16
Working Capital	191.47M	190.70M	112.39M	79.21M	88.89M	73.08M	66.28M	2.82M	8.74M	13.60M	22.61M	34.77M
Leverage & Debt
Debt to Equity	0.65	0.46	1.41	0.17	0.17	0.28	0.61	-2.41	-3.66	4.22	2.23	1.17
Interest Coverage TTM	-15.26	-16.71	-22.78	-37.20	-25.51	-19.20	-15.97	-14.98	-13.95	-13.93	-14.79	-13.52
Debt Ratio	0.39	0.32	0.59	0.14	0.15	0.22	0.38	1.71	1.38	0.81	0.69	0.54
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.19	-0.87	-0.72	-0.41	-0.43	-0.72	-1.74	-1.63	-1.67	-1.28	-1.31	-1.10
Free Cash Flow Per Share TTM	-0.65	-0.79	-0.73	-0.46	-0.41	-0.54	-0.85	-0.90	-1.04	-1.10	-1.20	-1.19
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-113,046.88%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-99,771.88%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-79.49%
Net Income Growth (1Y)	299.94%	37.51%	-30.80%	-56.40%	-55.72%	5.92%	45.44%	63.49%	55.34%	39.87%	101.87%	92.41%
EPS Growth (1Y)	177.79%	11.31%	-58.61%	-74.57%	-74.30%	-38.74%	32.86%	47.69%	50.36%	38.53%	101.09%	92.23%
Valuation Metrics
P/E TTM	-8.62	-5.61	-7.84	-12.30	-11.77	-7.21	-4.98	-4.25	-3.71	-1.23	-1.12	-0.83
P/B TTM	6.05	2.21	5.76	3.49	2.89	3.82	4.15	-14.54	-18.58	7.72	3.34	1.16
P/S TTM	-	-	-	-	-	-	-	-	-	-	-	831.44
Market Cap	763.55M	305.57M	299.22M	279.96M	260.54M	285.22M	274.94M	221.85M	185.24M	46.13M	42.53M	26.61M
Enterprise Value	561.57M	110.32M	179.07M	196.96M	166.29M	201.97M	246.44M	214.88M	173.33M	29.92M	15.75M	-10.54M
Calculated Values
Free Cash Flow TTM	-48.44M	-48.99M	-38.90M	-25.12M	-21.31M	-27.21M	-27.04M	-28.69M	-31.03M	-32.19M	-34.70M	-34.39M
Net Debt	-201.98M	-195.25M	-120.15M	-83.00M	-94.25M	-83.26M	-28.50M	-6.97M	-11.91M	-16.21M	-26.79M	-37.15M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-23Purchase

Owner: Manning, Paul B

Title: -

Shares: 550,458

Price/Share: $5.45

Value: $2,999,996.10

Shares Owned: 2,763,527

Relationship: Director

Ownership: Indirect

2025-07-28Sale

Owner: Nichols, William Garrett

Title: Chief Medical Officer

Shares: 937

Price/Share: $6.98

Value: $6,540.26

Shares Owned: 52,493

Relationship: Officer

Ownership: Direct

2025-06-30Sale

Owner: Nichols, William Garrett

Title: Chief Medical Officer

Shares: 781

Price/Share: $5.04

Value: $3,936.24

Shares Owned: 52,493

Relationship: Officer

Ownership: Direct

2025-03-19Sale

Owner: Tak, Paul Peter

Title: Chief Executive Officer

Shares: 400

Price/Share: $9.00

Value: $3,600.00

Shares Owned: 225,740

Relationship: Director,Officer

Ownership: Direct

2025-03-18Sale

Owner: Barone, Francesca

Title: Chief Scientific Officer

Shares: 32,146

Price/Share: $8.76

Value: $281,598.96

Shares Owned: 96,527

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-23	Manning, Paul B	Director	-	Indirect	Purchase	550,458	5.45	$2,999,996.10	2,763,527	4
2025-07-28	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	937	6.98	$6,540.26	52,493	4
2025-06-30	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	781	5.04	$3,936.24	52,493	4
2025-03-19	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	400	9.00	$3,600.00	225,740	4
2025-03-18	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	32,146	8.76	$281,598.96	96,527	4
2025-03-18	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	45,316	8.76	$396,968.16	52,493	4
2025-03-17	Schoch, Charles	Officer	See Remarks	Direct	Sale	5,000	8.83	$44,150.00	38,038	4
2025-03-17	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	31,278	8.82	$275,871.96	85,512	4/A
2025-01-15	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	14,322	7.23	$103,548.06	96,790	4
2025-01-15	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	21,704	7.23	$156,919.92	251,912	4
2025-01-15	Schoch, Charles	Officer	See Remarks	Direct	Sale	9,511	7.23	$68,764.53	43,038	4
2025-01-15	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	13,534	7.23	$97,850.82	110,673	4
2025-01-15	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	10,428	7.23	$75,394.44	79,320	4
2025-01-08	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	14,545	8.22	$119,559.90	111,112	4
2025-01-08	Schoch, Charles	Officer	See Remarks	Direct	Sale	9,971	8.22	$81,961.62	52,549	4
2025-01-08	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	13,673	8.22	$112,392.06	124,207	4
2025-01-08	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	21,172	8.22	$174,033.84	273,616	4
2025-01-08	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	10,799	8.22	$88,767.78	89,748	4
2024-12-16	Manning, Paul B	Director	-	Indirect	Purchase	1,250,000	6.00	$7,500,000.00	1,303,752	4
2024-11-29	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	20,392	4.56	$92,987.52	125,657	4
2024-11-29	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	22,081	4.56	$100,689.36	137,880	4
2024-11-29	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	13,935	4.56	$63,543.60	100,547	4
2024-11-29	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	48,847	4.56	$222,742.32	294,788	4
2024-10-15	Aguilar-Cordova, Estuardo…	TenPercentOwner	-	Direct	Sale	10,412	6.03	$62,784.36	919,461	4
2024-10-03	Aguilar-Cordova, Estuardo…	TenPercentOwner	-	Direct	Sale	1,800	6.85	$12,330.00	959,873	4
2024-07-17	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	14,051	6.47	$90,909.97	159,961	4
2024-07-17	Schoch, Charles	Officer	See Remarks	Direct	Sale	9,884	6.47	$63,949.48	62,520	4
2024-07-17	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	14,851	6.47	$96,085.97	146,049	4
2024-07-17	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	10,875	6.47	$70,361.25	114,482	4
2024-07-17	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	22,528	6.47	$145,756.16	330,735	4
2024-07-11	Tyagarajan, Seshu	Officer	Chief Technology Officer	Direct	Sale	13,330	5.97	$79,580.10	160,900	4
2024-07-11	Schoch, Charles	Officer	See Remarks	Direct	Sale	8,897	5.97	$53,115.09	72,404	4
2024-07-11	Tak, Paul Peter	Director,Officer	Chief Executive Officer	Direct	Sale	20,293	5.97	$121,149.21	353,263	4
2024-07-11	Barone, Francesca	Officer	Chief Scientific Officer	Direct	Sale	12,645	5.97	$75,490.65	174,012	4
2024-07-11	Nichols, William Garrett	Officer	Chief Medical Officer	Direct	Sale	9,769	5.97	$58,320.93	125,357	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

69.45%

Inst. Shares: 43,310,452

Shares Outstanding: 62,361,897

2025-12-31

44.44%

Inst. Shares: 23,535,718

Shares Outstanding: 52,958,644

2025-09-30

41.02%

Inst. Shares: 22,517,841

Shares Outstanding: 54,894,347

2025-06-30

44.33%

Inst. Shares: 22,827,446

Shares Outstanding: 51,489,929

2025-03-31

41.58%

Inst. Shares: 20,991,452

Shares Outstanding: 50,482,278

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	43,310,452	62,361,897	69.45%
2025-12-31	23,535,718	52,958,644	44.44%
2025-09-30	22,517,841	54,894,347	41.02%
2025-06-30	22,827,446	51,489,929	44.33%
2025-03-31	20,991,452	50,482,278	41.58%
2024-12-31	17,786,283	31,675,076	56.15%
2024-09-30	6,605,395	32,013,569	20.63%
2024-06-30	5,824,865	29,878,210	19.50%
2024-03-31	3,709,242	29,197,537	12.70%
2023-12-31	4,008,494	28,935,289	13.85%
2023-09-30	5,257,852	28,919,810	18.18%
2023-06-30	5,256,717	28,919,810	18.18%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Candel Therapeutics, Inc. (CADL) — SEC Financial Statements & Analysis

Candel Therapeutics, Inc. (CADL) is a biological products, (no diagnostic substances) company, incorporated in DE. Candel Therapeutics, Inc. trades on Nasdaq as: CADL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Candel Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.65x, a Price-to-Sales (P/S) ratio of 831.44x (TTM), a Price-to-Book (P/B) ratio of 6.05x (TTM), at a market cap of $763.55M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.65x
P/S TTM: 831.44x
P/B TTM: 6.05x
Market Cap: $763.55M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Candel Therapeutics, Inc. in?

Candel Therapeutics, Inc. (CADL) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CADL's market cap?

Candel Therapeutics, Inc. (CADL) has a market capitalization of $763.55M as of 2026-06-30.

What exchange does CADL trade on?

Candel Therapeutics, Inc. (CADL) trades on the Nasdaq.

Where is Candel Therapeutics, Inc. incorporated?

Candel Therapeutics, Inc. is incorporated in DE.